CA2432767A1 - Signal-1/signal-2 bifunctional peptide inhibitors - Google Patents

Signal-1/signal-2 bifunctional peptide inhibitors Download PDF

Info

Publication number
CA2432767A1
CA2432767A1 CA002432767A CA2432767A CA2432767A1 CA 2432767 A1 CA2432767 A1 CA 2432767A1 CA 002432767 A CA002432767 A CA 002432767A CA 2432767 A CA2432767 A CA 2432767A CA 2432767 A1 CA2432767 A1 CA 2432767A1
Authority
CA
Canada
Prior art keywords
peptide
sequence
signal
amino acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002432767A
Other languages
English (en)
French (fr)
Inventor
Joseph S. Murray
Teruna J. Siahaan
Yongbo Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2432767A1 publication Critical patent/CA2432767A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002432767A 2000-12-18 2001-12-17 Signal-1/signal-2 bifunctional peptide inhibitors Abandoned CA2432767A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/739,466 2000-12-18
US09/739,466 US7786257B2 (en) 2000-12-18 2000-12-18 Signal-1/signal-2 bifunctional peptide inhibitors
PCT/US2001/048632 WO2002050250A2 (en) 2000-12-18 2001-12-17 Signal-1/signal-2 bifunctional peptide inhibitors

Publications (1)

Publication Number Publication Date
CA2432767A1 true CA2432767A1 (en) 2002-06-27

Family

ID=24972431

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002432767A Abandoned CA2432767A1 (en) 2000-12-18 2001-12-17 Signal-1/signal-2 bifunctional peptide inhibitors

Country Status (8)

Country Link
US (1) US7786257B2 (https=)
EP (2) EP1404362B1 (https=)
JP (1) JP2004536783A (https=)
AT (1) ATE400293T1 (https=)
AU (1) AU2002230911A1 (https=)
CA (1) CA2432767A1 (https=)
DE (1) DE60134791D1 (https=)
WO (1) WO2002050250A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188218B2 (en) 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
WO2008067281A1 (en) * 2006-11-30 2008-06-05 Vance Products Incorporated D/B/A Cook Urological Incorporated Removable handle for medical device
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
MX2010001779A (es) * 2007-08-15 2010-07-06 Circassia Ltd Peptidos para vacunas.
AU2008317331B2 (en) * 2007-10-25 2013-08-29 The Scripps Research Institute Antibody-mediated disruption of quorum sensing in bacteria
DE102009040716B4 (de) * 2009-09-10 2011-07-14 Miltenyi Biotec GmbH, 51429 Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen
WO2011163572A2 (en) 2010-06-24 2011-12-29 University Of Kansas Bifunctional conjugate compositions and associated methods
EP3498300A1 (en) 2011-07-27 2019-06-19 University of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
US9913823B2 (en) * 2011-10-18 2018-03-13 Amorepacific Corporation SIRT 1 activator including syringaresinol
WO2018215506A1 (en) * 2017-05-23 2018-11-29 Université De Genève Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP0576842B1 (de) * 1992-06-11 2002-10-16 MERCK PATENT GmbH Verfahren und Mittel zum Nachweis von Listerien
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DE69840326D1 (de) 1997-03-27 2009-01-22 Csl Ltd Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
EP1246643A4 (en) * 1999-10-14 2005-05-11 Jeffery A Ledbetter DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN

Also Published As

Publication number Publication date
EP1932539A3 (en) 2008-10-29
US20050107585A1 (en) 2005-05-19
US7786257B2 (en) 2010-08-31
EP1404362A2 (en) 2004-04-07
DE60134791D1 (de) 2008-08-21
WO2002050250A2 (en) 2002-06-27
EP1404362B1 (en) 2008-07-09
AU2002230911A1 (en) 2002-07-01
WO2002050250A3 (en) 2004-01-08
EP1932539A2 (en) 2008-06-18
EP1404362A4 (en) 2005-06-01
ATE400293T1 (de) 2008-07-15
JP2004536783A (ja) 2004-12-09

Similar Documents

Publication Publication Date Title
US11981743B2 (en) Monoclonal antibody and a method thereof
US6984625B2 (en) Methods and compositions for modulating autoimmunity
Rodgers et al. MHC class Ib molecules bridge innate and acquired immunity
JP2021107444A (ja) 調節性ｔ細胞エピトープ、組成物およびその使用
RU2598719C2 (ru) Средства для лечения заболевания
US7786257B2 (en) Signal-1/signal-2 bifunctional peptide inhibitors
JP2021503276A (ja) 制御性ｔ細胞エピトープ
JPH08149981A (ja) Ｔ細胞α鎖による抗原特異的免疫制御の方法
WO2016131911A1 (en) Methods for the treatment and diagnosis of type 1 diabetes
TW202426486A (zh) 使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法
WO2001026679A2 (en) T-cells and molecules involved in immune regulation
JP2024537353A (ja) 改変された結合タンパク質及びその治療上の使用
Miloro Deciphering the role of the death receptor Fas/CD95 in T cell co-stimulation
GB2640828A (en) Methods and products for the generation and identification of T cells and TCRs
KR20220160640A (ko) 조절 t-세포 에피토프
Wall Structural and biophysical characterisation of T-cell receptor cross-reactivity in health and disease
Jangalwe Regulation of Alloreactive CD8 T Cell Responses by Costimulation and Inflammation
Chlewicki Structure, function and engineering of peptide-MHC binding receptors
Esser An examination of molecular antigen recognition by the T cell receptor and T cell-mediated apoptosis of self-reactive B cells using transgenic model systems
Barbaro et al. A New Strategy of Tumor Vaccination Based on Mammary Adenocarcinoma Cells Transduced with the MHC Class II Transactivator CIITA. L. Mortara1, P. Castellani2, R. Meazza3, G. Tosi1, A. De
Schlueter Characterization of a T cell receptor: Peptide/MHC binding interaction
Mackewicz Molecular and cellular features governing T cell responsiveness to a defined protein antigen
JPWO2021195492A5 (https=)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued